Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanoparticles, and polymeric microparticles or nanoparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
October 6, 2020
Assignee:
ASCENDIA PHARMACEUTICALS, LLC.
Inventors:
Vera Ivanova, Kaoru Maeda, Wan Wang, Dongwei Guo, Jingjun Huang
Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanoparticles, and polymeric microparticles or nanoparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.
Type:
Application
Filed:
June 3, 2019
Publication date:
January 2, 2020
Applicant:
ASCENDIA PHARMACEUTICALS, LLC
Inventors:
Vera IVANOVA, Kaoru MAEDA, Wan WANG, Dongwei GUO, Jingjun HUANG
Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanparticles, and polymeric microparticles or nanparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.
Type:
Application
Filed:
June 13, 2017
Publication date:
December 14, 2017
Applicant:
ASCENDIA PHARMACEUTICALS, LLC
Inventors:
Vera IVANOVA, Kaoru MAEDA, Wan WANG, Dongwei GUO, Jingjun HUANG